4Devarbhavi H? Dierkhising R, Kremers WK, et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol,2010,105 :2396-2404.
5Goldstein HM, WAllnce S, Anderson JH,et al. Transcatheterem bolism of abdominal tumors. Radiology?1976,120 : 539-545.
6Llovet JM, Real MI, Montana X,et al. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma j a randomised controlled trial. Lancet. 2002,18: 1734-1739.
7Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. Hepatol J, 2001,35:421-430.
8Sahara S,Kawai N,Sato M, et al. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs ( epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol, 2012, 35 : 1363-1371.
9Saccheri S,Lovaria A,Sangiovanni A, Nicolini A,De Fazio C, Ronchi G,Fasani P, Del Ninno E, Colombo M. Segmentaltranscatheter arterial chemoembolization treatment in patients withcirrhosis and inoperable hepatocellular carcinomas. J Vase IntervRadiol, 2002,13:995-999.
10MATO JM, LU SC. Role of S-adenosyl-L-methionine in liver health and injury. Hepatology ,2007,45 : 1306-1312.
